Glaucoma is the leading cause of irreversible vision loss, worldwide. The term glaucoma includes many different diseases, which are associated with differing risk factors, symptoms, treatment, and prognosis. All forms of glaucoma are characterized by the loss of the retinal ganglion cells (RGCs) and their axons that make up the optic nerve, which results in a cupping of the optic nerve head. This leads to optic nerve damage and visual field loss. Raised intraocular pressure (IOP) is the primary risk factor for glaucoma, and progression of disease will normally stop if the IOP is lowered by 30-50%. Consequently, treatment options for glaucoma are developed around lowering the IOP. Although it is possible to slow the progression of glaucoma using current treatment options, it is not possible to reverse vision loss that has resulted from the disease.
Most drugs prescribed for glaucoma can be placed into one of five drug classes. Prostaglandin analogues (PGAs) are generally used as a first-line treatment, with beta blockers (BBs), alpha adrenergic receptor agonists (AAs), carbonic anhydrase inhibitors (CAIs), and rho kinase inhibitors (RKIs) also frequently used, albeit generally as second-line therapies in combination with PGAs. PGAs can also be reformulated in sustained-release implants as opposed to topical treatments, and this is shown as a separate class within the forecast. Certain combinations of available drugs are marketed as part of fixed-dose combination (FDC) therapies. Cholinergic agonists, and alpha-adrenergic antagonists (AAA) can also be used for the treatment of glaucoma, although they are much less commonly prescribed compared with PGAs, BBs, AAs, CAIs, and RKIs. During the forecast period, several new classes of drug are expected to become available throughout the 7MM, including small interfering RNA and LRRK2 inhibitors providing ophthalmologists further options to help lower IOP.
Key Questions Answered
Most drugs prescribed for glaucoma can be placed into one of five drug classes. Prostaglandin analogues (PGAs) are generally used as a first-line treatment, with beta blockers (BBs), alpha adrenergic receptor agonists (AAs), carbonic anhydrase inhibitors (CAIs), and rho kinase inhibitors (RKIs) also frequently used, albeit generally as second-line therapies in combination with PGAs. PGAs can also be reformulated in sustained-release implants as opposed to topical treatments, and this is shown as a separate class within the forecast. Certain combinations of available drugs are marketed as part of fixed-dose combination (FDC) therapies. Cholinergic agonists, and alpha-adrenergic antagonists (AAA) can also be used for the treatment of glaucoma, although they are much less commonly prescribed compared with PGAs, BBs, AAs, CAIs, and RKIs. During the forecast period, several new classes of drug are expected to become available throughout the 7MM, including small interfering RNA and LRRK2 inhibitors providing ophthalmologists further options to help lower IOP.
Key Highlights
- During the 10-year forecast period, there are seven major pipeline products that are on track to launch, driving a total forecast growth of $657.8M in the 7MM by 2030.
- The glaucoma market is expected to grow from $2.85B in 2020 to $3.48B in 2030, a CAGR of 2%. The US is the biggest market of the 7MM, accounting for 75.0% market share in 2020. This is set to increase to 80.2% by 2030.
Key Questions Answered
- How will the glaucoma market landscape in the 7MM (US, France, Germany, Italy, Spain, UK, Japan) change from 2020-2030?
- What are the most promising late-stage pipeline products for glaucoma?
- How do the clinical and commercial attributes of late-stage pipeline products compare with one another, and against existing glaucoma treatment options?
- What are the remaining unmet needs in glaucoma therapeutics?
- What drivers and barriers will affect glaucoma therapy sales in the 7MM over the forecast period?
Scope
- Overview of glaucoma, including epidemiology, etiology, pathophysiology, symptoms, diagnosis, and current management strategies.
- Topline glaucoma therapeutic market revenue from 2020-2030. Annual cost of therapy and major pipeline product sales in this forecast period are included.
- Key topics covered include current glaucoma therapies, unmet needs and opportunities, and the drivers and barriers affecting treatment sales in the 7MM.
- Pipeline analysis: comprehensive data split across different phases, emerging novel trends under development, synopses of innovative early-stage projects, and detailed analysis of late-stage pipeline products.
- Analysis of the current and future market competition in the global glaucoma therapeutic market. Insightful review of the key industry drivers, constraints, and challenges. Each trend is independently researched to provide qualitative analysis of its implications.
Reasons to Buy
The report will enable you to:
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies, and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global sepsis therapeutic market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments, and companies likely to impact the sepsis therapeutic market in the future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships.
Table of Contents
1 Glaucoma: Executive Summary
2 Introduction
3 Disease Overview
4 Epidemiology
5 Disease Management
6 Competitive Assessment
7 Unmet Needs and Opportunity Assessment
8 R&D Strategies
9 Pipeline Assessment
10 Pipeline Valuation Analysis
11 Current and Future Players
List of Tables
List of Figures
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Pfizer
- Allergan
- Alcon
- Bausch & Lamb
- Nic0x
- Mallinckrodt Plc
- Santen
- Merck
- Bruschettini Srl
- Aerie Pharmaceuticals
- Otsuka Pharmaceutical
- Aton
- Thea Pharma
- Novatis
- Kowa Co Ltd
- Sandoz International
- OmniVision
- Eisai Co Ltd
- Concordia International
- Teofarma Srl
- Sanwa Kagaku Kenkyusho
- Ocular Therapeutix Inc
- ViSci Ltd
- Ono Pharmaceutical
- D. Western Therapeutics
- Sylentis SAU
- pH Pharma Co Ltd
